Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats. / Borlongan, C V; Stahl, C E; Keep, M F; Elmer, Eskil; Watanabe, S.

I: Neuroscience Letters, Vol. 279, Nr. 2, 2000, s. 73-76.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Borlongan, C V ; Stahl, C E ; Keep, M F ; Elmer, Eskil ; Watanabe, S. / Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats. I: Neuroscience Letters. 2000 ; Vol. 279, Nr. 2. s. 73-76.

RIS

TY - JOUR

T1 - Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats

AU - Borlongan, C V

AU - Stahl, C E

AU - Keep, M F

AU - Elmer, Eskil

AU - Watanabe, S

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Laboratory for Experimental Brain Research (013041000)

PY - 2000

Y1 - 2000

N2 - Cyclosporine-A (CsA) is the primary anti-rejection drug used for organ and neural transplantation therapy. In addition to its immunosuppressive action, CsA has been recently shown to exert neuroprotective and neurotrophic effects in the central nervous system when able to cross the blood-brain barrier. Postulated mechanisms for these CsA-induced beneficial effects include the drug's powerful inhibition of the calcium-dependent phosphatase calcineurin (CN) and blockade of the assembly of the mitochondrial permeability transition pore. We report here, for the first time, that adult Wistar rats treated with CsA (10 mg/kg per day, i.p. for 9 days) displayed significantly reduced septal CN expression in combination with enhanced levels of septal choline acetyltransferase (ChAT) immunoreactivity as compared to controls. The observed enhancement of septal ChAT immunoreactivity suggests potential therapeutic utility of CsA for brain disorders characterized by alterations of the cholinergic system.

AB - Cyclosporine-A (CsA) is the primary anti-rejection drug used for organ and neural transplantation therapy. In addition to its immunosuppressive action, CsA has been recently shown to exert neuroprotective and neurotrophic effects in the central nervous system when able to cross the blood-brain barrier. Postulated mechanisms for these CsA-induced beneficial effects include the drug's powerful inhibition of the calcium-dependent phosphatase calcineurin (CN) and blockade of the assembly of the mitochondrial permeability transition pore. We report here, for the first time, that adult Wistar rats treated with CsA (10 mg/kg per day, i.p. for 9 days) displayed significantly reduced septal CN expression in combination with enhanced levels of septal choline acetyltransferase (ChAT) immunoreactivity as compared to controls. The observed enhancement of septal ChAT immunoreactivity suggests potential therapeutic utility of CsA for brain disorders characterized by alterations of the cholinergic system.

KW - Alzheimer’s disease

KW - Septum

KW - Cholinergic system

KW - Immunosuppression

KW - Neurotrophic effects

KW - Calcineurin

KW - Mitochondrial permeability transition pore

U2 - 10.1016/S0304-3940(99)00962-3

DO - 10.1016/S0304-3940(99)00962-3

M3 - Article

VL - 279

SP - 73

EP - 76

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -